Inari Medical, Inc. (NARI)
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Investigation
04/16/2021
Initial Lawsuit
04/16/2021
Dismissal
05/19/2021
Investigation following Culper Research’s report alleging, among others, undisclosed ties to Redwood Scientific, unwanted autorenewal of subscriptions and controls over the company’s platform for licensed physicians.
04/14/2021
Culper Research publishes a ‘short’ report alleging (twitter feed), among others, undisclosed ties to Redwood Scientific, unwanted autorenewal of subscriptions and lack of controls over the company’s platform for licensed physicians. The report goes on comparing the company’s practices to the Redwood Scientific fraud, categorizing the company a “direct marketing cash pit” engaging in “ARR From Subscriptions, Autoshipping, Cancellations, and “Money Back Guarantees.””
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$9 | $11.84 | $-2.84 | -23.99% |
This is a class action on behalf of persons and entities that purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that many of LifeMD’s executives were associated with Redwood Scientific when it was charged for unlawful autoshipping, abusive telemarketing, and false claims, and that they employed similar practices at the Company;
(2) that LifeMD engaged in autoshipping products to unwilling customers to record recurring revenue and the Company made it difficult to cancel such subscriptions;
(3) that certain of the purportedly licensed physicians on the Company’s platform were not in fact licensed and faced disciplinary action;
(4) that, as a result of the foregoing practices, the Company was reasonably likely to face regulatory scrutiny and/or reputational harm; and
(5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On 05/19/2021, plaintiff voluntarily dismissed the complaint.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.